The global cell and gene therapy CDMO market size accounted for USD 8.07 billion in 2025 and is forecasted to hit around USD 74.03 billion by 2034, representing a CAGR of 27.92% from 2025 to 2034. The North America market size was estimated at USD 2.59 billion in 2024 and is expanding at a CAGR of 28.05% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy CDMO Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy CDMO Market, by Phase
8.1.1 Pre-clinical
8.1.1.1. Market Revenue and Forecast
8.1.2. Clinical
8.1.2.1. Market Revenue and Forecast
9.1. Cell and Gene Therapy CDMO Market, by Product Type
9.1.1. Gene Therapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Gene-Modified Cell Therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Cell Therapy
9.1.3.1. Market Revenue and Forecast
10.1. Cell and Gene Therapy CDMO Market, by Indication
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Infectious Diseases
10.1.2.1. Market Revenue and Forecast
10.1.3. Neurological Disorders
10.1.3.1. Market Revenue and Forecast
10.1.4. Rare Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Phase
11.1.2. Market Revenue and Forecast, by Product Type
11.1.3. Market Revenue and Forecast, by Indication
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Phase
11.1.4.2. Market Revenue and Forecast, by Product Type
11.1.4.3. Market Revenue and Forecast, by Indication
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Phase
11.1.5.2. Market Revenue and Forecast, by Product Type
11.1.5.3. Market Revenue and Forecast, by Indication
11.2. Europe
11.2.1. Market Revenue and Forecast, by Phase
11.2.2. Market Revenue and Forecast, by Product Type
11.2.3. Market Revenue and Forecast, by Indication
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Phase
11.2.4.2. Market Revenue and Forecast, by Product Type
11.2.4.3. Market Revenue and Forecast, by Indication
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Phase
11.2.5.2. Market Revenue and Forecast, by Product Type
11.2.5.3. Market Revenue and Forecast, by Indication
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Phase
11.2.6.2. Market Revenue and Forecast, by Product Type
11.2.6.3. Market Revenue and Forecast, by Indication
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Phase
11.2.7.2. Market Revenue and Forecast, by Product Type
11.2.7.3. Market Revenue and Forecast, by Indication
11.3. APAC
11.3.1. Market Revenue and Forecast, by Phase
11.3.2. Market Revenue and Forecast, by Product Type
11.3.3. Market Revenue and Forecast, by Indication
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Phase
11.3.4.2. Market Revenue and Forecast, by Product Type
11.3.4.3. Market Revenue and Forecast, by Indication
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Phase
11.3.5.2. Market Revenue and Forecast, by Product Type
11.3.5.3. Market Revenue and Forecast, by Indication
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Phase
11.3.6.2. Market Revenue and Forecast, by Product Type
11.3.6.3. Market Revenue and Forecast, by Indication
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Phase
11.3.7.2. Market Revenue and Forecast, by Product Type
11.3.7.3. Market Revenue and Forecast, by Indication
11.4. MEA
11.4.1. Market Revenue and Forecast, by Phase
11.4.2. Market Revenue and Forecast, by Product Type
11.4.3. Market Revenue and Forecast, by Indication
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Phase
11.4.4.2. Market Revenue and Forecast, by Product Type
11.4.4.3. Market Revenue and Forecast, by Indication
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Phase
11.4.5.2. Market Revenue and Forecast, by Product Type
11.4.5.3. Market Revenue and Forecast, by Indication
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Phase
11.4.6.2. Market Revenue and Forecast, by Product Type
11.4.6.3. Market Revenue and Forecast, by Indication
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Phase
11.4.7.2. Market Revenue and Forecast, by Product Type
11.4.7.3. Market Revenue and Forecast, by Indication
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Phase
11.5.2. Market Revenue and Forecast, by Product Type
11.5.3. Market Revenue and Forecast, by Indication
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Phase
11.5.4.2. Market Revenue and Forecast, by Product Type
11.5.4.3. Market Revenue and Forecast, by Indication
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Phase
11.5.5.2. Market Revenue and Forecast, by Product Type
11.5.5.3. Market Revenue and Forecast, by Indication
12.1. Avid Bioservices
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Catalent
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Charles River Lobaoraties
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Curia
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Emergent BioSolutions
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eurofins
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. FUJIFILM Diosynth Biotechnologies
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Genscript
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Lonza
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer CentreOne
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample